| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 | Dec'17 | Sep'17 | Jun'17 | Mar'17 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Collaboration revenue | ||||||||||||
588 | 563 | 441 | 392 | 270 | 1,196 | 1,602 | 1,395 | 1,129 | - | - | - | - |
Operating expenses: | ||||||||||||
Research and development | ||||||||||||
29,310 | 20,344 | 25,691 | 22,827 | 20,536 | 16,267 | 13,394 | 10,290 | 7,997 | 9,575 | 4,946 | 4,056 | 2,799 |
General and administrative | ||||||||||||
7,770 | 5,778 | 6,038 | 5,538 | 4,857 | 5,102 | 3,843 | 4,527 | 3,828 | 2,686 | 1,718 | 1,982 | 1,892 |
Total operating expenses | ||||||||||||
37,080 | 26,122 | 31,729 | 28,365 | 25,393 | 21,369 | 17,237 | 14,817 | 11,825 | 12,262 | 6,664 | 6,038 | 4,691 |
Loss from operations | ||||||||||||
-36,492 | -25,559 | -31,288 | -27,973 | -25,123 | -20,173 | -15,635 | -13,422 | -10,696 | -12,262 | -6,664 | -6,038 | -4,691 |
Other income: | ||||||||||||
Changes in fair value of convertible preferred stock tranche liability | ||||||||||||
- | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 876 |
Interest income | ||||||||||||
1,161 | 1,392 | 1,661 | 1,703 | 1,271 | 1,387 | 1,487 | 996 | 479 | 356 | 137 | 35 | 12 |
Total other income | ||||||||||||
1,161 | 1,392 | 1,661 | 1,703 | 1,271 | 1,387 | 1,487 | 996 | 479 | 356 | 137 | 35 | -863 |
Net loss | ||||||||||||
-35,331 | -24,167 | -29,627 | -26,270 | -23,852 | -18,786 | -14,148 | -12,426 | -10,217 | -11,905 | -6,527 | -6,002 | -5,554 |
Net loss per share-basic and diluted | ||||||||||||
-0.78 | -0.55 | -0.67 | -0.61 | -0.64 | 2.86 | -0.38 | -0.34 | -4.09 | -3.92 | -2.78 | -2.61 | -2.79 |
Weighted-average common shares outstanding-basic and diluted | ||||||||||||
45,151 | 44,105 | 43,904 | 43,075 | 37,384 | 37,573 | 37,273 | 36,860 | 2,500 | 3,278 | 2,351 | 2,296 | 1,992 |